Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

BMC Pharmacology and Toxicology

Volumn 16, Issue 1, 2015, Pages

  Sagwa, Evans L ^a   Ruswa, Nunurai ^b   Mavhunga, Farai ^b   Rennie, Timothy ^c   Leufkens, Hubert G M ^a   Mantel Teeuwisse, Aukje K ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b National Tuberculosis and Leprosy Programme   (Namibia)

^c UNIVERSITY OF NAMIBIA   (Namibia)

Author keywords

Adverse events; Aminoglycosides; Audiometry; MDR TB; Pharmacovigilance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; PYRAZINAMIDE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; AUDIOLOGY; BODY WEIGHT; CHI SQUARE TEST; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE; HEARING; HEARING AID; HEARING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NAMIBIAN; RETROSPECTIVE STUDY; RISK FACTOR; SPEECH REHABILITATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT WITHDRAWAL; ADOLESCENT; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CHILD; COINFECTION; COMPARATIVE STUDY; HEARING LOSS; HEARING TEST; HIV INFECTIONS; INFANT; MICROBIOLOGY; MIDDLE AGED; NAMIBIA; NEWBORN; PRESCHOOL CHILD; PROCEDURES; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT; VIROLOGY;

ADOLESCENT; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COINFECTION; HEARING LOSS; HEARING TESTS; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KANAMYCIN; LOGISTIC MODELS; MIDDLE AGED; NAMIBIA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84949671091     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/s40360-015-0036-7     Document Type: Article

References (44)

1. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: Switzerland 2008.
2. Ministry of Health and Social Services (MoHSS). National Guidelines for the Management of Tuberculosis. 3rd ed. Windhoek: MoHSS; 2012.
3. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621-9. www.thelancet.com/infection Vol 10 September 2010.
4. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:797-800.
5. Cianfrone G, Pentangelo D, Altissimi G, Turchetta R. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci. 2011;15:601-36.
6. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40:1277-86.
7. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13:119-26.
8. Olusanya BO, Neumann J, Saunders JE. The global burden of disabling hearing impairment: a call to action. Bull World Health Organ. 2014;92:367-73.
9. Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. Ototoxicity of Amikacin. Antimicrob Agents Chemother. 1976;9:956-61.
10. World Health Organization (WHO). Report of an informal consultation on strategies for prevention of hearing impairment from ototoxic drugs. Geneva: Switzerland 1994.
11. Jacob LCB, Aguiar FP, Tomiasi AA, Tschoeke SN, De Bitencourt RF. Auditory monitoring in ototoxicity. Braz J Otorhinolaryngol. 2006;72:836-44.
12. Singh Chauhan R, Saxena RK, Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose Throat J. 2011;90:218-22.
13. Fausti SA, Wilmington DJ, Helt PV, Helt WJ, Konrad-Martin D. Hearing health and care: The need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev. 2005;42:45.
14. Bardien S, de Jong G, Schaaf HS, Harris T, Fagan J, Petersen L. Aminoglycoside-induced hearing loss: South Africans at risk. South African Med J. 2009;99:440-1.
15. Perletti G, Vral A, Patrosso MC, Marras E, Ceriani I, Willems P, et al. Prevention and modulation of aminoglycoside ototoxicity (Review). Mol Med Rep. 2008;1:3-13.
16. Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66:1815-20.
17. Verdel BM, van Puijenbroek EP, Souverein PC, Leufkens HGM, Egberts ACG. Drug-related nephrotoxic and ototoxic reactions: a link through a predictive mechanistic commonality. Drug Saf. 2008;31:877-84.
18. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7:5.
19. World Bank. Namibia | Data [Internet]. 2015. [cited 2015 Jul 18]. Available from: http://data.worldbank.org/country/namibia. Accessed on 18 July 2015.
20. UNAIDS. UNAIDS report on the global AIDS epidemic. UNAIDS Global Report, 2013. Geneva: UNAIDS; 2013.
21. World Health Organization (WHO). Global Tuberculosis Report, 2014. Geneva: World Health Organization; 2014.
22. Venkatesh KK, Swaminathan S, Andrews JR, Mayer KH. Tuberculosis and HIV co-infection: screening and treatment strategies. Drugs. 2011;71:1133-52.
23. Monte S, Fenwick JD, Monteiro EF. Irreversible ototoxicity associated with zalcitabine. Int J STD AIDS. 1997;8:201-2.
24. Rey D, L'Héritier A, Lang J. Severe Ototoxicity in a Health Care Worker Who Received Postexposure and Nevirapine after Occupational Exposure to HIV. Clin Infect Dis. 2002;34:418-9.
25. Simdon J, Watters D, Bartlett S, Connick E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis. 2001;32:1623-7.
26. Batista A, Vieira C, Greco DB. Otoneurological manifestations associated with antiretroviral therapy. Rev Soc Bras Med Trop. 2008;41:65-9.
27. Katijah K. Is there a need for ototoxicity monitoring in patients with HIV/AIDS? African J Pharm Pharmacol. 2010;4:574-9.
28. Ministry of Health and Social Services (MoHSS). National Guidelines for Antiretroviral Therapy. 3rd ed. Windhoek: MoHSS; 2010.
29. ASHA. Degree of Hearing Loss [Internet]. ASHA; [cited 2015 Oct 15]. Available from: http://www.asha.org/public/hearing/Degree-of-Hearing-Loss/. Accessed on 15 October 2015.
30. Reza M, Abtahi B, Gholami K. The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients. Iran J Pharm Res. 2011;10:905-11.
31. Sataloff J, Wagner S, Menduke H. Kanamycin ototoxicity in healthy men. Arch Otolaryngol. 1964;80:413-7.
32. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861.
33. Szczepanik W, Kaczmarek P, Jezowska-Bojczuk M. Oxidative activity of copper(II) complexes with aminoglycoside antibiotics as implication to the toxicity of these drugs. Bioinorg Chem Appl. 2004;10:55-68.
34. Sha SH, Schacht J. Prevention of aminoglycoside-induced hearing loss. Keio J Med. 1997;46:115-9.
35. Lopez-Gonzalez MA, Guerrero JM, Torronteras R, Osuna C, Delgado F. Ototoxicity caused by aminoglycosides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs. J Pineal Res. 2000;28:26-33.
36. Cheng AG, Cunningham LL, Rubel EW. Mechanisms of hair cell death and protection. Curr Opin Otolaryngol Head Neck Surg. 2005;13:343-8.
37. Karasawa T, Wang Q, David LL, Steyger PS. Calreticulin binds to gentamicin and reduces drug-induced ototoxicity. Toxicol Sci. 2011;124:378-87.
38. Harris T, Bardien S, Schaaf HS, Petersen L, Jong G de, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. South African Med J. 2012. 363-6.
39. Harris T, Heinze B. Open Access Guide to Audiology and Hearing Aids for Otolaryngologists. Cape Town: UCT; 2013. p. 1-17.
40. Schouten JT, Lockhart DW, Rees TS, Collier AC, Marra CM. A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people. BMC Infect Dis. 2006;6:28.
41. Pechere J-C, Dugal R. Clinical Pharmacokinetics of Aminoglycoside Antibiotics. Clin Pharmacokinet. 1979;4:170-99.
42. De Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside. Int J Tuberc Lung Dis. 2002;6:622-7.
43. Nwobodo N. Therapeutic drug monitoring in a developing nation: a clinical guide. JRSM Open. 2014;5:2054270414531121.
44. Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010;65:654-8.